You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: February 28, 2024

Bendamustine hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for bendamustine hydrochloride and what is the scope of patent protection?

Bendamustine hydrochloride is the generic ingredient in five branded drugs marketed by Accord Hlthcare, Apotex, Breckenridge, Dr Reddys, Eugia Pharma, Kindos, Mylan Labs Ltd, Nang Kuang Pharm Co, Cephalon, Eagle Pharms, Baxter Hlthcare Corp, Hospira, and Slayback Pharma Llc, and is included in fifteen NDAs. There are twenty-seven patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Bendamustine hydrochloride has one hundred and forty-four patent family members in thirty-two countries.

There are sixteen drug master file entries for bendamustine hydrochloride. Ten suppliers are listed for this compound. There are six tentative approvals for this compound.

Recent Clinical Trials for bendamustine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Philippe Armand, MD, PhDPhase 2
GenmabPhase 2
Cancer Research UKPhase 2

See all bendamustine hydrochloride clinical trials

Generic filers with tentative approvals for BENDAMUSTINE HYDROCHLORIDE
Applicant Application No. Strength Dosage Form
⤷  Try a Trial⤷  Try a Trial100MG/VIALPOWDER;IV (INFUSION)
⤷  Try a Trial⤷  Try a Trial25MG/VIALPOWDER;IV (INFUSION)
⤷  Try a Trial⤷  Try a Trial100MG/VIALPOWDER;IV (INFUSION)

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for bendamustine hydrochloride
Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity
Medical Subject Heading (MeSH) Categories for bendamustine hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for bendamustine hydrochloride
Paragraph IV (Patent) Challenges for BENDAMUSTINE HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
BELRAPZO Injection bendamustine hydrochloride 100 mg/4 mL (25 mg/mL) multiple-dose vials 205580 1 2018-07-17
BENDEKA Injection bendamustine hydrochloride 100 mg/4 mL (25 mg/mL) multiple-dose vials 208194 1 2017-05-04
TREANDA Injection bendamustine hydrochloride 90 mg/mL, 0.5 mL and 2 mL in single- dose vials 022249 1 2014-06-19
TREANDA Injection bendamustine hydrochloride 25 mg/vial and 100 mg/vial 022249 10 2013-06-04

US Patents and Regulatory Information for bendamustine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eagle Pharms BELRAPZO bendamustine hydrochloride SOLUTION;INTRAVENOUS 205580-001 May 15, 2018 AP RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Mylan Labs Ltd BENDAMUSTINE HYDROCHLORIDE bendamustine hydrochloride POWDER;IV (INFUSION) 204104-001 Apr 28, 2023 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eagle Pharms BENDEKA bendamustine hydrochloride SOLUTION;IV (INFUSION) 208194-001 Dec 7, 2015 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for bendamustine hydrochloride

Country Patent Number Title Estimated Expiration
New Zealand 556435 Bendamustine pharmaceutical compositions for lyophilisation ⤷  Try a Trial
Australia 2015207940 Liquid Formulations of Bendamustine ⤷  Try a Trial
Japan 2018048153 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 (METHOD OF TREATING BENDAMUSTINE-RESPONSIVE CONDITIONS IN PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATION) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.